Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies
11:13am, Monday, 12'th Jun 2023
Editas (EDIT) announces positive preliminary safety and efficacy data from patients treated with its lead drug, EDIT-301, in the RUBY and EdiTHAL studies to treat SCD and TDT, respectively.
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
04:15pm, Tuesday, 06'th Jun 2023
An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m.
7 Short-Squeeze Stocks Set for a May Rally
05:38pm, Monday, 22'nd May 2023
A practice designed for only the most daring traders, the best short-squeeze stocks to buy now could yield tremendous gains. To be sure, approaching this sector means staring at the possibility of sev
Editas Medicine, Inc. (EDIT) Bank of America Global Healthcare Conference Call Transcript
10:17pm, Saturday, 13'th May 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) Bank of America Global Healthcare Conference Call May 9, 2023 8:00 PM ET Company Participants Gilmore O'Neill - President, CEO & Director Conference Call Participa
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that a scientific abstract detailing safety and effic
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
12:57pm, Monday, 08'th May 2023
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focu
Editas Medicine, Inc. (EDIT) Q1 2023 Earnings Call Transcript
02:30pm, Friday, 05'th May 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2023 Results Conference Call May 5, 2023 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - Ch
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates
09:54am, Friday, 05'th May 2023
Editas Medicine (EDIT) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.74 per share a year ago.
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
06:45am, Monday, 01'st May 2023
CAMBRIDGE, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Fr
The 3 Most Promising Gene Editing Stocks to Buy in 2023
04:51pm, Friday, 28'th Apr 2023
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring rad
Why Shares of Editas Medicine Rose Monday
02:50pm, Monday, 17'th Apr 2023
Editas has undergone several cost-cutting measures. The company announced last week that it was appointing a new chairman of the board and independent director.
2 Stocks Under $15 Per Share to Consider
09:00am, Sunday, 16'th Apr 2023
Editas Medicine is encountering headwinds, but its ability to innovate could help it turn things around. Snap's large and growing ecosystem of young users promises to drive revenue growth for years.
Editas (EDIT) Soars 20.3%: Is Further Upside Left in the Stock?
05:22am, Friday, 14'th Apr 2023
Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
02:25pm, Thursday, 13'th Apr 2023
Against the backdrop of a solid day on Wall Street, CRISPR Therapeutics (NASDAQ: CRSP ) distinguished itself, popping up nearly 16%. The catalyst appears to center on CRISPR's single-dose therapy for
Proceed With Caution When Considering These 5 Ultra-Popular Stocks
05:25am, Thursday, 13'th Apr 2023
AMC Entertainment and Netflix are fighting against the fragmentation of public entertainment interests. SNDL and Tilray are struggling, as are most Canadian cannabis companies.
